A double blind, randomised placebo controlled within patient cross-over study to assess the efficacy and safety of indacaterol (150 micrograms once daily) in the symptomatic treatment of pulmonary lymphangioleiomyomatosis (LAM)
Latest Information Update: 24 Jun 2016
At a glance
- Drugs Indacaterol (Primary)
- Indications Lymphangioleiomyomatosis
- Focus Therapeutic Use
- Acronyms TILT
- Sponsors Novartis
- 27 Nov 2013 New trial record